We’re making an even greater impact against viral diseases and breaking new ground in cancer and inflammation to help build a healthier world for all.
Explore Our Pipeline- Our Therapeutic Leadership
- Pursuing What’s Next
Our Therapeutic Leadership
For 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed, and we’ve helped cure millions of people with hepatitis C around the world. Our decades of research in emerging viruses allowed us to deliver the first approved treatment for COVID-19. And together with Kite, a Gilead Company, which is focused on cell therapy, we’re making an impact in multiple types of cancer.
Known for our commitment to innovation and access, we are poised to meet our ambition, set in 2019, to deliver 10+ transformative therapies by 2030.
Pursuing What’s Next
We continue to set bold ambitions in our pursuit of a healthier world for all people.
We’re building on our legacy in virology by helping to end the HIV epidemic for everyone, everywhere, including through the development of long-acting options for PrEP (pre-exposure prophylaxis), by aiming to eliminate hepatitis C as a public health problem, and preparing for future infectious diseases. In oncology, we’re driving innovative discovery to positively impact the lives of more than 500,000 people with various types of cancer around the world by 2030. In inflammation, we’re committed to addressing unmet patient needs with the development of new approaches in chronic inflammation and in diseases such as primary biliary cholangitis and fibrosis.
It will take more than medicine alone to solve the greatest challenges in virology, oncology and inflammation. Beyond our science, we’re committed to working with communities and partners around the world to improve healthcare access, eliminate barriers to care and advance health equity.
OUR IMPACT
Transformative therapies
to patients by 2030, a goal set in 2019
Clinical stage programs
Potential clinical stage
opt-in assets
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research, development and external collaborations.
